drugset / Trial / NCT04601181
Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies
Phase 1
Unknown
20 enrolled
Fundamenta Therapeutics, Ltd.
The First Affiliated Hospital of USTC (Anhui Provincial Hospital) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, nonrandomized, open-label, study to evaluate the safety and clinical activity of allogeneic CAR-T targeting CD22 in patients with refractory or relapsed CD22-positive B cell malignancies
Timeline
- Start
- 2020-10-23
- Primary completion
- 2022-10-15
- Completion
- 2023-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ThisCART22 | Cell therapy | — | Other |